RAC Approves Cellectis’s UCART123 Phase 1 study protocols in AML and BPDCN
Cellectis, a biopharmaceutical company focused on developing immunotherapies based on gene edited CAR T-cells (UCART), has announced the National Institute…
Pharmaceuticals, Biotechnology and Life Sciences
Cellectis, a biopharmaceutical company focused on developing immunotherapies based on gene edited CAR T-cells (UCART), has announced the National Institute…
MDxHealth’s laboratory in Nijmegen, The Netherlands has received ISO 13485:2016 certification for the design, development, manufacture and distribution of in…
Allergan’s indirect subsidiaries Forest Laboratories, LLS and Forest Pharmaceuticals, Inc. are about to pay $38 million for bad sales and…
French vaccines developer Valneva has closed the share issuance in connection with MVM Life Science Partners LLP`s investment in the…
Catalyst Pharmaceuticals, a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, has announced…
BD has launched the BD Neopak 2.25 mL prefillable glass syringe, specifically designed for biopharmaceutical manufacturers that develop, manufacture and…
Eli Lilly and Boehringer Ingelheim Pharmaceuticals have announced that Basaglar (insulin glargine injection 100 units/mL) is available by prescription in…
As some of you might know, pharmaceuticaldaily.com has recently redesigned its website as it added some new features and has…
Hansa Medical, a biopharmaceutical company focusing on novel immunomodulatory enzymes, has announced that the Committee for Orphan Medicinal Products (COMP)…
Galapagos has tested its filgotinib – JAK1 inhibitor – in a phase 2 study, for the patients with Chron’s disease, and…